Prevalence of B-cell (CD19+) population and BAFF-R expression in the peripheral blood of CLL patients or healthy donors
| . | % positive cells . | ||
|---|---|---|---|
| CD19+ . | BAFF-R+ . | CD19+, BAFF-R+ . | |
| Healthy donors | |||
| 1 | 1.6 | 1.8 | 1.7 |
| 2 | 3.0 | 3.5 | 3.1 |
| 3 | 1.8 | 1.5 | 1.8 |
| 4 | 1.8 | 1.8 | 1.8 |
| 5 | 2.7 | 3.4 | 2.8 |
| CLL patients | |||
| 1 | 85.3 | 89.4 | 86 |
| 2 | 23.2 | 33.4 | 24 |
| 3 | 79.5 | 88.7 | 82 |
| 4 | 39.8 | 42.4 | 41 |
| 5 | 36.2 | 48.9 | 38 |
| 6 | 26.0 | 42.0 | 30 |
| 7 | 40.8 | 43.2 | 42 |
| 8 | 36.7 | 33.3 | 37 |
| 9 | 60.4 | 65.0 | 62 |
| 10 | 29.8 | 26.9 | 31 |
| 11 | 56.3 | 53.4 | 55 |
| . | % positive cells . | ||
|---|---|---|---|
| CD19+ . | BAFF-R+ . | CD19+, BAFF-R+ . | |
| Healthy donors | |||
| 1 | 1.6 | 1.8 | 1.7 |
| 2 | 3.0 | 3.5 | 3.1 |
| 3 | 1.8 | 1.5 | 1.8 |
| 4 | 1.8 | 1.8 | 1.8 |
| 5 | 2.7 | 3.4 | 2.8 |
| CLL patients | |||
| 1 | 85.3 | 89.4 | 86 |
| 2 | 23.2 | 33.4 | 24 |
| 3 | 79.5 | 88.7 | 82 |
| 4 | 39.8 | 42.4 | 41 |
| 5 | 36.2 | 48.9 | 38 |
| 6 | 26.0 | 42.0 | 30 |
| 7 | 40.8 | 43.2 | 42 |
| 8 | 36.7 | 33.3 | 37 |
| 9 | 60.4 | 65.0 | 62 |
| 10 | 29.8 | 26.9 | 31 |
| 11 | 56.3 | 53.4 | 55 |
Primary PBMNCs from either the healthy donors (1-5) or from the patients (1-11) were stained either with CD19-FITC, or BAFF-R-PE antibodies, or both of the antibodies and analyzed by flow cytometry.